Related Experiment Video
Updated: May 26, 2026

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain
Published on: January 4, 2018
Inavolisib-induced fulminant-like diabetes and hyperosmolar hyperglycemic state: a case report.
Hongyu Li1, Chenxiang Cao1, Lixia Jin1
1Department of Endocrinology, Beijing Tsinghua Changgung Hospital, School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing, China.
Inavolisib, a PI3Kα inhibitor, can cause severe hyperglycemia and Hyperosmolar Hyperglycemic State (HHS) even in patients without prior diabetes. Prompt recognition and insulin therapy are crucial for managing this on-target side effect.
Area of Science:
- Oncology
- Endocrinology
- Pharmacology
Background:
- Inavolisib is a PI3Kα inhibitor used for advanced breast cancer.
- It carries a risk of hyperglycemia, an on-target adverse effect.
- Clinical endocrinologists may lack awareness of Inavolisib-induced hyperglycemia risks and management.
Related Concept Videos
Hyperosmolar Hyperglycemic State
Type I Diabetes III: Clinical Manifestations
Type I Diabetes II: Pathophysiology
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Diabetes Insipidus II: Pathophysiology
Complications of Diabetes Mellitus
